<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Help Page</title>
  <style>
    body {
      font-family: sans-serif;
      line-height: 1.6;
      margin: 0;
      padding: 0;
    }

    header, section {
      padding: 2em;
    }

    header {
      background: #333;
      color: white;
      text-align: center;
    }

    section {
      border-bottom: 1px solid #ccc;
    }

    h2 {
      margin-top: 0;
    }

    nav {
      background: #f4f4f4;
      padding: 1em;
      text-align: center;
    }

    nav a {
      margin: 0 1em;
      text-decoration: none;
      color: #333;
    }

    nav a:hover {
      text-decoration: underline;
    }
  </style>
</head>
<body>

  <header>
    <h1>Welcome to the Help Page</h1>
    <p>Select a section below or use a direct link to jump where you need</p>
  </header>

  <nav>
    <a href="#section1">Arterial Plaque Outcome Case Study Outline V1</a>
    <a href="#section2">Section 2</a>
    <a href="#section3">Section 3</a>
    <a href="#section4">Section 4</a>
  </nav>

  <section id="section1">
    <h2>Arterial Plaque Outcome Case Study Outline V1</h2>
    <section id="case-study">
      <h2>Outcome Case Study Outline</h2>
      <p><strong>Evaluating the Effect of a Dietary Supplement containing Nattokinase and soluble Stacked Terpenes (Borneol and Trans Cinnamaldehyde) (NBT) on Arterial Plaque Reduction in Adults with Mild to Moderate Atherosclerosis.</strong></p>
    
      <h3>1. Introduction</h3>
      <h4>1.1 Title</h4>
      <p>Study and evaluation of the effectiveness of NBT supplementation in reducing arterial plaque levels and improving vascular health in adults with mild to moderate atherosclerosis.</p>
    
      <h4>1.2 Study Objectives</h4>
      <p><strong>Primary Objective:</strong> To evaluate the effect of oral NBT supplementation in adults with moderate arterial plaque.</p>
      <p><strong>Secondary Objectives:</strong></p>
      <ul>
        <li>Evaluate quality of life improvements.</li>
        <li>Assess tolerability of NBT supplementation.</li>
      </ul>
    
      <h4>1.3 Study Design</h4>
      <p><strong>Type:</strong> Case study</p>
      <p><strong>Duration:</strong> 16 weeks</p>
      <p><strong>Setting:</strong> Outpatient clinics and research centers</p>
      <p><strong>Participants:</strong></p>
      <ul>
        <li>20 Adults aged 40-75 years</li>
        <li>Diagnosed with mild to moderate atherosclerosis based on medical history and imaging</li>
        <li>Willing to comply with the study protocol and provide informed consent</li>
        <li>No major cardiovascular events in the last 6 months</li>
      </ul>
      <p><strong>Exclusion Criteria:</strong></p>
      <ul>
        <li>Severe cardiovascular disease</li>
        <li>Active bleeding disorders or history of major bleeding</li>
        <li>Pregnancy or breastfeeding</li>
        <li>Chronic kidney disease (eGFR &lt; 30)</li>
        <li>Current use of blood thinners or anticoagulants that might interfere with NBT</li>
        <li>History of hypersensitivity to soy products</li>
      </ul>
    
      <h4>1.4 Intervention</h4>
      <p>NBT oral dietary supplement: 1 capsule BID (Twice Daily)</p>
    
      <h4>1.5 Outcome Measures</h4>
      <p><strong>Primary Outcome:</strong></p>
      <ul>
        <li>Reduction in arterial plaque assessed by CIMT or CAC score</li>
        <li>CIMT via high-resolution ultrasound</li>
        <li>CAC via CT scan</li>
      </ul>
      <p><strong>Secondary Outcomes:</strong></p>
      <ul>
        <li><strong>Blood Biomarkers:</strong> Fibrinogen, D-dimer, CRP, Lipid profile, PAI-1, tPA</li>
        <li><strong>Blood Pressure:</strong> Systolic and diastolic changes</li>
        <li><strong>Vascular Function:</strong> Flow-mediated dilation (FMD) of brachial artery</li>
      </ul>
    
      <h4>1.6 Study Timeline</h4>
      <ul>
        <li>Screening and Enrollment: 2 weeks</li>
        <li>Treatment Period: 16 weeks</li>
        <li>Study Start Estimate: November 2025</li>
        <li>Recruitment: September - October 2025</li>
        <li>Intervention: November 2025 - February 2026</li>
        <li>Follow-up: March - April 2026</li>
        <li>Post-intervention Assessments: Week 17</li>
        <li>Optional 6-month follow-up for sustained effects</li>
      </ul>
    
      <h4>1.7 Data Collection and Analysis</h4>
      <p><strong>Data Collection:</strong></p>
      <ul>
        <li>Medical history and demographics</li>
        <li>Baseline and post-intervention measurements: arterial plaque, lipid profile, biomarkers, blood pressure, FMD</li>
      </ul>
      <p><strong>Statistical Analysis:</strong></p>
      <ul>
        <li>Primary: Change in CIMT or CAC using paired t-tests or ANCOVA</li>
        <li>Secondary: Correlation with inflammatory and fibrinolytic markers</li>
        <li>Subgroup: Age, sex, and baseline plaque severity</li>
      </ul>
    
      <h4>1.8 Sample Size Calculation</h4>
      <p>Assess whether there is a moderate effect with NBT (e.g., 10-15% reduction in plaque compared to starting point) in the studied population.</p>
    </section>
    
  </section>

  <section id="section2">
    <h2>Section 2: Returning Users</h2>
    <p>Information tailored for users who have already interacted with us.</p>
  </section>

  <section id="section3">
    <h2>Section 3: Technical Support</h2>
    <p>Resources and contact info for those experiencing technical issues.</p>
  </section>

  <section id="section4">
    <h2>Section 4: Billing and Payments</h2>
    <p>Answers to common billing questions and how to manage your account.</p>
  </section>

</body>
</html>

